Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus XERAVA.
CHLOROMYXIN vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
CHLOROMYXIN is not a recognized drug. No data available.
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic